) Healthcare unit and
Johnson & Johnson
) Janssen Pharmaceuticals recently collaborated with Portola
Pharmaceuticals Inc. to evaluate the safety of PRT4445 in
combination with blood thinner Xarelto (rivaroxaban).
The proof-of-concept study intends to evaluate the safety of
PRT4445 in combination with Xarelto across multiple dosages to
determine the dose of PRT4445 that will be able to reverse the
anticoagulant activity of Xarelto in emergency situations. The
study is expected to be completed by year-end.
Following the agreement, Portola will receive an undisclosed
amount from Bayer and Johnson & Johnson. Bayer and Johnson
& Johnson will provide development and regulatory guidance to
Portola for the study. Portola retains all global development and
commercialization rights for PRT4445.
We note that Xarelto, already approved for multiple
indications, offers significant commercial potential. Xarelto is
jointly developed by Bayer and the Janssen Research and
Development unit of Johnson & Johnson. Johnson & Johnson
is responsible for marketing the drug in the US, while Bayer is
exclusively responsible for the marketing of the drug outside the
Xarelto was approved for the lucrative stroke prevention in
nonvalvular atrial fibrillation (SPAF) indication in 2011.
Xarelto is also approved for the treatment of pulmonary embolism
(PE) and the prevention of recurrent deep vein thrombosis (DVT)
and PE in adults. Bayer and Johnson & Johnson are looking to
expand the drug's label further.
Bayer carries a Zacks Rank #2 (Buy). Other large pharma stocks
Eli Lilly and Company
) also carry a comparable rank.
BAYER A G -ADR (BAYRY): Free Stock Analysis
JOHNSON & JOHNS (JNJ): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.